合併症のない尿路感染症治療の世界市場レポート 2025年

合併症のない尿路感染症治療市場規模は、今後数年で急成長が見込まれます。2029年には101億3,000万米ドルに成長し、CAGRは10.5%となります。予測期間における成長の背景には、認知度向上キャンペーン、医療アクセスの増加、ヘルスケアインフラの整備、研究資金の増加、医薬品マーケティングおよび規制環境の向上があります。予測期間の主な動向としては、迅速診断テストの進歩、ドラッグデリバリーシステムの革新、家庭用診断キットの需要、スマートフォンアプリの開発、デジタルヘルスソリューションの採用などが挙げられます。

合併症のない尿路感染症治療市場は、院内感染の発生率の増加により成長するとみられます。これらの感染症は、患者が入院中に発症するもので、多くの場合、抗生物質耐性菌、不十分な感染対策、長期入院、免疫システムの低下などが原因となっています。院内感染の増加は、ヘルスケア環境における尿路感染症の効果的な治療戦略の緊急の必要性を浮き彫りにし、この分野での技術革新と投資を促進しています。例えば、オーストラリア保健福祉研究所の2024年6月の報告書によると、公立病院における患者治療日数2,250万日の間に報告された黄色ブドウ球菌血流感染症（SABSI）は1,668例でした。これは1万患者日あたり0.74件のSABSI症例数であり、院内感染がヘルスケア施設に与える影響を明確に示しています。

合併症を伴わない尿路感染症（UTI）治療市場の主要企業は、増加する抗生物質耐性に対抗し、一般細菌感染症の治療効果を向上させるため、アミノペニシリン系抗生物質の開発に注力しています。アミノペニシリン系抗生物質は、感染症の原因となる細菌を標的として排除することで、合併症のない尿路結石の治療に役立ちます。アミノペニシリン系抗生物質は、細菌の増殖と生存に不可欠な細菌細胞壁の合成を阻害することによって作用します。例えば、2024年4月、英国のバイオテクノロジー研究会社であるユーティリティ・セラピューティクス社は、大腸菌、プロテウス・ミラビリス、ブドウ球菌の感受性株によって引き起こされる成人女性の合併症のない尿路結石を治療するピブヤ（pivmecillinam）のFDA承認を取得しました。Pivmecillinamはアミノペニシリン系抗生物質で、細菌の細胞壁合成を阻害することにより作用します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界合併症のない尿路感染症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の合併症のない尿路感染症治療市場：成長率分析
• 世界の合併症のない尿路感染症治療市場の実績：規模と成長, 2019-2024
• 世界の合併症のない尿路感染症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界合併症のない尿路感染症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の合併症のない尿路感染症治療市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゲポチダシン
• プロベネシド
• スルホンアミド
• テトラサイクリン
• ニトロフラン
• 世界の合併症のない尿路感染症治療市場感染源別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 院内尿路感染症（UTI）
• 市中感染性尿路感染症（UTI）
• 世界の合併症のない尿路感染症治療市場性別：、実績と予測, 2019-2024, 2024-2029F, 2034F
• 男
• 女性
• 世界の合併症のない尿路感染症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 婦人科・泌尿器科クリニック
• 小売薬局
• オンラインドラッグストア
• 世界の合併症のない尿路感染症治療市場ゲポチダシンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口製剤
• 注射剤
• 世界の合併症のない尿路感染症治療市場プロベネシドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口製剤
• 世界の合併症のない尿路感染症治療市場、スルホンアミドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トリメトプリム-スルファメトキサゾール（TMP-SMX）
• 世界の合併症のない尿路感染症治療市場テトラサイクリンのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドキシサイクリン
• ミノサイクリン
• 世界の合併症のない尿路感染症治療市場ニトロフランの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニトロフラントイン

第7章 地域別・国別分析

• 世界の合併症のない尿路感染症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の合併症のない尿路感染症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 合併症のない尿路感染症治療市場：競合情勢
• 合併症のない尿路感染症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Abbott Laboratories
• GlaxoSmithKline PLC
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Company Limited
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Lupin Limited
• Almirall S.A
• Iterum Therapeutics PLC
• Inmunotek S.L.
• Fimbrion Therapeutics Inc.
• Utility Therapeutics Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 合併症のない尿路感染症治療市場2029：新たな機会を提供する国
• 合併症のない尿路感染症治療市場2029：新たな機会を提供するセグメント
• 合併症のない尿路感染症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Uncomplicated urinary tract infection (UTI) treatment involves diagnosing and managing infections that affect healthy individuals with normal urinary tracts, typically confined to the bladder and not involving structural or functional abnormalities. The primary objectives of treatment include eradicating the infection, alleviating symptoms, and preventing potential complications.

The main drug classes used in uncomplicated UTI treatment include gepotidacin, probenecid, sulfonamides, tetracyclines, and nitrofurans. Gepotidacin is an investigational antibiotic from the triazaacenaphthylene class, effective against both gram-positive and gram-negative pathogens. These infections can originate from sources such as hospital-acquired and community-acquired UTIs, affecting both males and females. Distribution channels for these treatments include hospital pharmacies, gynecology and urology clinics, retail pharmacies, and online drugstores.

The uncomplicated urinary tract infection treatment market research report is one of a series of new reports from The Business Research Company that provides uncomplicated urinary tract infection treatment market statistics, including the uncomplicated urinary tract infection treatment industry's global market size, regional shares, competitors with uncomplicated urinary tract infection treatment market share, detailed uncomplicated urinary tract infection treatment market segments, market trends and opportunities, and any further data you may need to thrive in the uncomplicated urinary tract infection treatment industry. This uncomplicated urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The uncomplicated urinary tract infection treatment market size has grown rapidly in recent years. It will grow from $6.12 billion in 2024 to $6.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to rising prevalence of urinary tract infections (UTIs), growing awareness and diagnosis, aging population, improving healthcare policies and insurance coverage, and increasing government initiatives.

The uncomplicated urinary tract infection treatment market size is expected to see rapid growth in the next few years. It will grow to $10.13 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to rising awareness campaigns, increasing healthcare access, rising healthcare infrastructure, increasing research funding, rising pharmaceutical marketing and regulatory environment. Major trends in the forecast period include advancements in rapid diagnostic tests, innovation in drug delivery systems, demand for home diagnostic kits, development of smartphone apps, and adoption of digital health solutions.

The uncomplicated urinary tract infection treatment market is set to grow due to the increasing incidence of hospital-acquired infections. These infections are acquired by patients during their hospital stays, often due to antibiotic-resistant bacteria, inadequate infection control measures, prolonged hospitalization, and compromised immune systems. The rise in hospital-acquired infections highlights the urgent need for effective strategies to treat urinary tract infections within healthcare settings, driving innovation and investment in this field. For example, according to the Australian Institute of Health and Welfare's June 2024 report, there were 1,668 cases of staphylococcus aureus bloodstream infections (SABSI) reported during 22.5 million patient care days in public hospitals. This resulted in a rate of 0.74 SABSI cases per 10,000 patient days, underscoring the impact of hospital-acquired infections on healthcare facilities.

Leading companies in the uncomplicated urinary tract infection (UTI) treatment market are focusing on developing aminopenicillin antibiotics to combat rising antibiotic resistance and improve the efficacy of treatments for common bacterial infections. Aminopenicillin antibiotics help treat uncomplicated UTIs by targeting and eliminating the bacteria responsible for the infections. They work by inhibiting the synthesis of bacterial cell walls, which is critical for bacterial growth and survival. For example, in April 2024, Utility Therapeutics Ltd., a UK-based biotechnology research firm, received FDA approval for Pivya (pivmecillinam) to treat uncomplicated UTIs in adult females caused by susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. Pivmecillinam is an aminopenicillin antibiotic that works by blocking bacterial cell wall synthesis.

In November 2023, Pharmavite, a US-based dietary supplement company, acquired Bonafide Health for $425 million. This acquisition allows Pharmavite to broaden its product portfolio and strengthen its presence in the dietary supplement market, offering consumers a wider variety of health and wellness solutions. Bonafide Health is a US-based pharmaceutical company that produces dietary supplements and herbal remedies designed to provide relief and support for women dealing with urinary tract infections.

Major companies operating in the uncomplicated urinary tract infection treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Almirall S.A, Iterum Therapeutics PLC, Inmunotek S.L., Fimbrion Therapeutics Inc., Utility Therapeutics Ltd.

North America was the largest region in the uncomplicated urinary tract infection treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uncomplicated urinary tract infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the uncomplicated urinary tract infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The uncomplicated urinary tract infection treatment market consists of sales of ciprofloxacin, levofloxacin, and ceftriaxonea. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Uncomplicated Urinary Tract Infection Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on uncomplicated urinary tract infection treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for uncomplicated urinary tract infection treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The uncomplicated urinary tract infection treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Gepotidacin; Probenecid; Sulfonamide; Tetracycline; Nitrofuran
• 2) By Source Of Infection: Hospital-Acquired Urinary Tract Infection (UTI); Community-Acquired Urinary Tract Infection (UTI)
• 3) By Gender: Male; Female
• 4) By Distribution Channel: Hospital Pharmacies; Gynecology And Urology Clinics; Retail Pharmacies; Online Drug Stores
• Subsegments:
• 1) By Gepotidacin: Oral Formulation; Injectable Formulation
• 2) By Probenecid: Oral Formulation
• 3) By Sulfonamide: Trimethoprim-Sulfamethoxazole (TMP-SMX)
• 4) By Tetracycline: Doxycycline; Minocycline
• 5) By Nitrofuran: Nitrofurantoin
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Uncomplicated Urinary Tract Infection Treatment Market Characteristics

3. Uncomplicated Urinary Tract Infection Treatment Market Trends And Strategies

4. Uncomplicated Urinary Tract Infection Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Uncomplicated Urinary Tract Infection Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Uncomplicated Urinary Tract Infection Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Uncomplicated Urinary Tract Infection Treatment Market Growth Rate Analysis
• 5.4. Global Uncomplicated Urinary Tract Infection Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Uncomplicated Urinary Tract Infection Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Uncomplicated Urinary Tract Infection Treatment Total Addressable Market (TAM)

6. Uncomplicated Urinary Tract Infection Treatment Market Segmentation

• 6.1. Global Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gepotidacin
• Probenecid
• Sulfonamide
• Tetracycline
• Nitrofuran
• 6.2. Global Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital-Acquired Urinary Tract Infection (UTI)
• Community-Acquired Urinary Tract Infection (UTI)
• 6.3. Global Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Male
• Female
• 6.4. Global Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Gynaecology And Urology Clinics
• Retail Pharmacies
• Online Drug Stores
• 6.5. Global Uncomplicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Gepotidacin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Formulation
• Injectable Formulation
• 6.6. Global Uncomplicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Probenecid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Formulation
• 6.7. Global Uncomplicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Sulfonamide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trimethoprim-Sulfamethoxazole (TMP-SMX)
• 6.8. Global Uncomplicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Tetracycline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Doxycycline
• Minocycline
• 6.9. Global Uncomplicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Nitrofuran, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitrofurantoin

7. Uncomplicated Urinary Tract Infection Treatment Market Regional And Country Analysis

• 7.1. Global Uncomplicated Urinary Tract Infection Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Uncomplicated Urinary Tract Infection Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Uncomplicated Urinary Tract Infection Treatment Market

• 8.1. Asia-Pacific Uncomplicated Urinary Tract Infection Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Uncomplicated Urinary Tract Infection Treatment Market

• 9.1. China Uncomplicated Urinary Tract Infection Treatment Market Overview
• 9.2. China Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Uncomplicated Urinary Tract Infection Treatment Market

• 10.1. India Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Uncomplicated Urinary Tract Infection Treatment Market

• 11.1. Japan Uncomplicated Urinary Tract Infection Treatment Market Overview
• 11.2. Japan Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Uncomplicated Urinary Tract Infection Treatment Market

• 12.1. Australia Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Uncomplicated Urinary Tract Infection Treatment Market

• 13.1. Indonesia Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Uncomplicated Urinary Tract Infection Treatment Market

• 14.1. South Korea Uncomplicated Urinary Tract Infection Treatment Market Overview
• 14.2. South Korea Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Uncomplicated Urinary Tract Infection Treatment Market

• 15.1. Western Europe Uncomplicated Urinary Tract Infection Treatment Market Overview
• 15.2. Western Europe Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Uncomplicated Urinary Tract Infection Treatment Market

• 16.1. UK Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Uncomplicated Urinary Tract Infection Treatment Market

• 17.1. Germany Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Uncomplicated Urinary Tract Infection Treatment Market

• 18.1. France Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Uncomplicated Urinary Tract Infection Treatment Market

• 19.1. Italy Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Uncomplicated Urinary Tract Infection Treatment Market

• 20.1. Spain Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Uncomplicated Urinary Tract Infection Treatment Market

• 21.1. Eastern Europe Uncomplicated Urinary Tract Infection Treatment Market Overview
• 21.2. Eastern Europe Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Uncomplicated Urinary Tract Infection Treatment Market

• 22.1. Russia Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Uncomplicated Urinary Tract Infection Treatment Market

• 23.1. North America Uncomplicated Urinary Tract Infection Treatment Market Overview
• 23.2. North America Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Uncomplicated Urinary Tract Infection Treatment Market

• 24.1. USA Uncomplicated Urinary Tract Infection Treatment Market Overview
• 24.2. USA Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Uncomplicated Urinary Tract Infection Treatment Market

• 25.1. Canada Uncomplicated Urinary Tract Infection Treatment Market Overview
• 25.2. Canada Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Uncomplicated Urinary Tract Infection Treatment Market

• 26.1. South America Uncomplicated Urinary Tract Infection Treatment Market Overview
• 26.2. South America Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Uncomplicated Urinary Tract Infection Treatment Market

• 27.1. Brazil Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Uncomplicated Urinary Tract Infection Treatment Market

• 28.1. Middle East Uncomplicated Urinary Tract Infection Treatment Market Overview
• 28.2. Middle East Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Uncomplicated Urinary Tract Infection Treatment Market

• 29.1. Africa Uncomplicated Urinary Tract Infection Treatment Market Overview
• 29.2. Africa Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Source Of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Uncomplicated Urinary Tract Infection Treatment Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Uncomplicated Urinary Tract Infection Treatment Market Competitive Landscape And Company Profiles

• 30.1. Uncomplicated Urinary Tract Infection Treatment Market Competitive Landscape
• 30.2. Uncomplicated Urinary Tract Infection Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Uncomplicated Urinary Tract Infection Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. AstraZeneca PLC
• 31.3. Bristol-Myers Squibb Company
• 31.4. Abbott Laboratories
• 31.5. GlaxoSmithKline PLC
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Daiichi Sankyo Company Limited
• 31.8. Dr. Reddy's Laboratories Ltd.
• 31.9. Cipla Ltd.
• 31.10. Lupin Limited
• 31.11. Almirall S.A
• 31.12. Iterum Therapeutics PLC
• 31.13. Inmunotek S.L.
• 31.14. Fimbrion Therapeutics Inc.
• 31.15. Utility Therapeutics Ltd.

32. Global Uncomplicated Urinary Tract Infection Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Uncomplicated Urinary Tract Infection Treatment Market

34. Recent Developments In The Uncomplicated Urinary Tract Infection Treatment Market

35. Uncomplicated Urinary Tract Infection Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Uncomplicated Urinary Tract Infection Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Uncomplicated Urinary Tract Infection Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Uncomplicated Urinary Tract Infection Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer